Cite
HARVARD Citation
Clerkin, J. et al. (n.d.). TMOD-12. ESTABLISHING A CLINICALLY RELEVANT MODEL OF MESENCHYMAL GLIOBLASTOMA (GBM) TO STUDY RESPONSE TO STANDARD OF CARE TREATMENT AND IMMUNE CHECKPOINT INHIBITION (ICI).. Neuro-oncology. p. ii230. [Online].